In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corus Pharma Inc.

Division of Gilead Sciences Inc.
www.coruspharma.com

Latest From Corus Pharma Inc.

Deal Statistics Quarterly, Q4 2006

We present another installment of our quarterly review of dealmaking-for October-December 2006. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics and research industries.

BioPharmaceutical Medical Device

European Consolidation: Serious Competition for Big Pharma?

Merck KGAA surprised observers when it announced the €10.6 billion takeover of Europe's biggest biotech, Serono. There was more consolidation to come. That same day, the Danish pharmaceutical group Nycomed Group said it would acquire Altana Pharma for about €4.5 billion in cash. Only a couple days later, UCB SA entered the fray with the acquisition of Schwarz Pharma AG for €4.2 billion in cash and stock. Can these bulked up companies present serious competition for Big Pharma on the licensing front?

BioPharmaceutical Europe

IPO Failures Can Set Up Biotech Successes

Did the 31 biotechs who pulled IPOs since 2003 destroy value? By and large, no-thanks to a growing variety of financing and exit options, most thanks to Pharma's increasing appetite for high-value deals and deeper private equity pockets.

BioPharmaceutical Business Strategies

The Vioxx Withdrawal: Can the Industry Avoid the Whirlpool?

The Vioxx withdrawal is one of those seminal events that, because of the players involved--the industry's largest companies, some of their most valuable drugs, both the European and American regulatory structures--holds up a mirror to an entire industry. Given the record breaking valuation slides, the market is taking a very critical look at the industry's strategies; so should the people who run it.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Gilead Sciences Inc.
  • Senior Management
  • William Baker, PhD, VP, Research
    Jonathan P Mow, VP, Commercial & Bus. Dev.
  • Contact Info
  • Corus Pharma Inc.
    Phone: (206) 728-5090
    2025 1st Ave., Ste. 800
    Seattle, WA 98121
    USA
UsernamePublicRestriction

Register